Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $2.0 million.

  • Relay Therapeutics' Capital Expenditures fell 100.44% to -$1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $636,000, marking a year-over-year decrease of 70.22%. This contributed to the annual value of $2.0 million for FY2024, which is 51.09% down from last year.
  • Latest data reveals that Relay Therapeutics reported Capital Expenditures of $2.0 million as of FY2024, which was down 51.09% from $4.1 million recorded in FY2023.
  • In the past 5 years, Relay Therapeutics' Capital Expenditures ranged from a high of $9.1 million in FY2022 and a low of $1.9 million during FY2020.
  • In the last 3 years, Relay Therapeutics' Capital Expenditures had a median value of $4.1 million in 2023 and averaged $5.1 million.
  • Per our database at Business Quant, Relay Therapeutics' Capital Expenditures crashed by 75.87% in 2020 and then soared by 161.08% in 2022.
  • Over the past 5 years, Relay Therapeutics' Capital Expenditures (Yearly) stood at $1.9 million in 2020, then soared by 79.75% to $3.5 million in 2021, then surged by 161.08% to $9.1 million in 2022, then crashed by 54.47% to $4.1 million in 2023, then crashed by 51.09% to $2.0 million in 2024.